

[Paromomycin](#)

Essential medicine status

Section:

[6. Anti-infective medicines](#) [6.5. Antiprotozoal medicines](#) [6.5.2. Antileishmaniasis medicines](#)

ATC codes: [A07AA06](#)

EMLc

Indication

Visceral leishmaniasis ICD11 code: [1F54.0](#)

INN

Paromomycin

Medicine type

Chemical agent

Antibiotic groups

[WATCH](#)

List type

Core

Formulations

Parenteral > General injections > IM: 750 mg paromomycin base (as sulfate)

EML status history

First added in 2007 ([TRS 946](#))

Changed in 2007 ([TRS 950](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Paromomycin](#)

[DrugBank](#)

[Paromomycin](#)

Summary of evidence and Expert Committee recommendations



Paromomycin was considered at the 15th Expert Committee meeting in March 2007, where paromomycin solution for intramuscular (IM) injection was added to the Model List. The Expert Committee concluded that paromomycin was effective in terms of effect on standard endpoints, such as initial and final cure, for the treatment of visceral leishmaniasis in children and adults. Paromomycin is licensed in India, and was granted orphan drug designation by the US Food and Drug Administration (FDA) in March 2005 and the European Medicines Agency (EMA) in April 2005. The EMLc Subcommittee endorsed the listing of paromomycin IM injection on the first EMLc.